Protalix BioTherapeutics, Inc. (DE) (PLX): Price and Financial Metrics


Protalix BioTherapeutics, Inc. (DE) (PLX)

Today's Latest Price: $4.46 USD

0.12 (-2.62%)

Updated Jan 25 6:40pm

Add PLX to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

PLX Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for PLX is -1.84 -- better than merely 4.12% of US stocks.
  • Equity multiplier, or assets relative to shareholders' equity, comes in at -1.61 for Protalix BioTherapeutics Inc; that's greater than it is for merely 5.22% of US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for PLX comes in at -27.08% -- higher than that of just 9.89% of stocks in our set.
  • Stocks that are quantitatively similar to PLX, based on their financial statements, market capitalization, and price volatility, are AGEN, ABUS, OMER, GNFT, and DNN.
  • Visit PLX's SEC page to see the company's official filings. To visit the company's web site, go to www.protalix.com.

PLX Stock Price Chart Interactive Chart >

Price chart for PLX

PLX Price/Volume Stats

Current price $4.46 52-week high $4.86
Prev. close $4.58 52-week low $2.04
Day low $4.46 Volume 203,500
Day high $4.59 Avg. volume 247,580
50-day MA $3.73 Dividend yield N/A
200-day MA $3.61 Market Cap 148.68M

Protalix BioTherapeutics, Inc. (DE) (PLX) Company Bio


Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx protein expression system in Israel and internationally. The company was founded in 1993 and is based in Carmiel, Israel.


PLX Latest News Stream


Event/Time News Detail
Loading, please wait...

PLX Latest Social Stream


Loading social stream, please wait...

View Full PLX Social Stream

Latest PLX News From Around the Web

Below are the latest news stories about Protalix BioTherapeutics Inc that investors may wish to consider to help them evaluate PLX as an investment opportunity.

Protalix BioTherapeutics to Participate in Upcoming Investor Conferences in January

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced that the Company's management will participate in virtual 1x1 investor meetings at the 10th Annual LifeSci Partners Corporate Access Event and present a corporate overview at the H.C. Wainwright BioConnect 2021 Conference. Details regarding the two events are as follows:

Yahoo | January 4, 2021

PLX: Final Results for BRIDGE and A Letter to Shareholders

By John Vandermosten, CFA NYSE:PLX READ THE FULL PLX RESEARCH REPORT On December 30, 2020, Protalix BioTherapeutics, Inc. (NYSE:PLX) announced final results of its BRIDGE Phase III open-label, switch-over clinical trial of lead candidate pegunigalsidase alfa (PRX-102) in Fabry Disease. Protalix President and CEO, Dror Bashan simultaneously issued its 2020 Letter to Shareholders . This is the

Yahoo | January 4, 2021

Protalix BioTherapeutics and Chiesi Global Rare Diseases Announce Final Results of BRIDGE Phase III Open-Label, Switch-Over Clinical Trial Evaluating Pegunigalsidase Alfa for the Treatment of Fabry Disease

CARMIEL, Israel and BOSTON, Dec. 30, 2020 /PRNewswire/ -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (TASE:PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®…

PR Newswire | December 30, 2020

Protalix BioTherapeutics Issues 2020 Letter to Shareholders

Protalix BioTherapeutics, Inc. (NYSE American: PLX) (TASE: PLX), a biopharmaceutical company focused on the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx® plant cell-based protein expression system, today announced the following letter from its President and Chief Executive Officer, Dror Bashan, to its shareholders and the investment community.

Yahoo | December 30, 2020

Have Insiders Been Buying Protalix BioTherapeutics, Inc. (NYSEMKT:PLX) Shares This Year?

We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that...

Yahoo | December 21, 2020

Read More 'PLX' Stories Here

PLX Price Returns

1-mo N/A
3-mo 25.63%
6-mo 20.87%
1-year 27.07%
3-year -35.36%
5-year -47.53%
YTD 22.87%
2020 10.67%
2019 5.47%
2018 -52.95%
2017 50.23%
2016 -56.86%

Continue Researching PLX

Want to see what other sources are saying about Protalix BioTherapeutics Inc's financials and stock price? Try the links below:

Protalix BioTherapeutics Inc (PLX) Stock Price | Nasdaq
Protalix BioTherapeutics Inc (PLX) Stock Quote, History and News - Yahoo Finance
Protalix BioTherapeutics Inc (PLX) Stock Price and Basic Information | MarketWatch


Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9688 seconds.